Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

New Analysis of the 104 ABPM Study Presented at the American Heart

Association

http://www.nicox.com

SOPHIA ANTIPOLIS, France, November 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in hypertensive volunteers was designed to compare the 24-hour blood pressure profiles of naproxcinod 750 mg bid and naproxen 500 mg bid. Naproxcinod is NicOx' lead investigational product and the first compound in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents.

This new post hoc analysis was accepted by the American Heart Association scientific panel and compared the mean 24-hour systolic blood pressure (SBP) as measured by ABPM in the two groups (i.e. naproxcinod vs. naproxen), at the end of the 2 weeks of active treatment. The mean 24-hour SBP showed a difference of 2.4 mmHg (standard error 0.87 mmHg) in favor of naproxcinod as compared to naproxen (p=0.007) after 2 weeks of treatment. Interestingly, for the daytime measurements (the 8 hours following the morning dose), the mean 8-hour SBP showed a difference of 4.4 mmHg (standard error 0.98 mmHg) in favor of naproxcinod as compared to naproxen (p<0.0001) after 2 weeks of treatment.

"It was very interesting and rewarding to share these promising results with the medical community at the American Heart Association Scientific Sessions, which is one of the leading cardiology congresses worldwide," commented Jacques Djian MD, Cardiologist and Vice-President Translational Medicine at NicOx. "This new analysis of the blood pressure data from the 104 study follows the excellent top-line r
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Staying true ... to craft a digital product that makes the world ... with Global Biological Standards Institute (GBSI) to redesign their ... clean, and most importantly, strategy-based. , "Biomedical research is ... - much less to promote it in a narrative ...
(Date:4/21/2015)... , April 21, 2015 ... and development, custom automation, and contract manufacturing, and  ... accessible flow cytometry and cell sorting technology for ... develop a novel flow cytometry platform. ... NanoCellect Biomedical has developed a microchip-based cell sorting ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that it will release ... on Tuesday, April 28, 2015. United Therapeutics ... 2015, at 9:00 a.m. Eastern Time.  The teleconference is ... A rebroadcast of the teleconference will be available for ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... 18 Danaher Corporation (NYSE: DHR ) announced today ... indirect wholly owned subsidiary, to acquire all of the issued and ... pence per share implying an aggregate price of approximately GBP 50 ... The offer enjoys the recommendation of the Board of Genetix who ...
... , Toronto Stock Exchange Symbol: ... (TSX: MS) today provided the following update on corporate developments: ... -----------------, , The Company has completed its substantive review of ... drug candidate for the treatment of multiple sclerosis (MS). BioMS ...
... , , , , ... stem cell based,technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical,team ... 36 year old Norwegian,patient in a hospital in Beijing. The ... stem cells as well as cancer daughter,cells. The amazing outcome ...
Cached Biology Technology:Danaher Offers to Acquire Genetix Group plc for GBP 50 million pounds Sterling (USD $82 million) 2BioMS Medical provides corporate update 2BioMS Medical provides corporate update 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... office on the Texas A&M University campus, Dr. Marty Dickman,s ... pursuit of scientific excellence that,s what,s fun," Dickman said. ... is to understand what the problems are, how things work ... Dickman paused briefly and with gratitude recently to reflect on ...
... Ten researchers at the University of California, Riverside have ... of Science ( AAAS ). Including this year,s fellows, the ... with AAAS Fellow distinction is 190. Election as a ... peers. This year AAAS gave this honor to 503 of ...
... Iowa State University two of them are also affiliated ... been named fellows of the American Association for the Advancement ... their award citations are: Srinivas ... of Computer Engineering, "For distinguished contributions to high performance computational ...
Cached Biology News:Marty Dickman named AAAS Fellow 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 3AAAS honors Iowa State, Ames Lab researchers for distinguished science 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: